{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+400+mg&page=4",
    "query": {
      "intervention": "Placebo 400 mg",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1034,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+400+mg&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+400+mg&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T14:09:50.699Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04988035",
      "title": "ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Danicopan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Remdesivir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 201,
      "start_date": "2021-08-03",
      "completion_date": "2022-04-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Fresno, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04988035"
    },
    {
      "nct_id": "NCT03015532",
      "title": "Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "HTX-011",
          "type": "DRUG"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        },
        {
          "name": "Bupivicaine HCl",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Heron Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 285,
      "start_date": "2017-01-13",
      "completion_date": "2018-05-16",
      "has_results": true,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 24,
      "location_summary": "Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 13 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015532"
    },
    {
      "nct_id": "NCT01203514",
      "title": "The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Infant, Newborn",
        "Infant, Low Birth Weight",
        "Infant, Small for Gestational Age",
        "Infant, Premature",
        "Anemia, Neonatal"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Sham Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "24 Hours",
        "maximum_age": "96 Days",
        "sex": "ALL",
        "summary": "24 Hours to 96 Days"
      },
      "enrollment_count": 318,
      "start_date": "1997-08",
      "completion_date": "2000-08",
      "has_results": false,
      "last_update_posted_date": "2017-09-26",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01203514"
    },
    {
      "nct_id": "NCT02219685",
      "title": "Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus Infection"
      ],
      "interventions": [
        {
          "name": "LDV/SOF",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": "2014-08",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2018-11-16",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02219685"
    },
    {
      "nct_id": "NCT04089852",
      "title": "Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Contraceptive Devices",
        "Long-Acting Reversible Contraception",
        "Analgesia",
        "Adolescent Health",
        "Gynecology"
      ],
      "interventions": [
        {
          "name": "Nitrous oxide gas for inhalation",
          "type": "DRUG"
        },
        {
          "name": "Oxygen Gas for Inhalation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "24 Years",
        "sex": "FEMALE",
        "summary": "14 Years to 24 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2021-06-01",
      "completion_date": "2021-11-01",
      "has_results": false,
      "last_update_posted_date": "2022-09-16",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04089852"
    },
    {
      "nct_id": "NCT03509285",
      "title": "A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Alprazolam Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cenobamate placebo",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Cenobamate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2017-03-08",
      "completion_date": "2017-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03509285"
    },
    {
      "nct_id": "NCT03650452",
      "title": "A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epilepsy",
        "Dravet Syndrome",
        "Lennox-Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "TAK-935",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 141,
      "start_date": "2018-08-08",
      "completion_date": "2020-07-20",
      "has_results": true,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03650452"
    },
    {
      "nct_id": "NCT00600015",
      "title": "Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib + Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib + Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2008-02",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2022-03-10",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 16,
      "location_summary": "Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 13 more",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600015"
    },
    {
      "nct_id": "NCT04605588",
      "title": "A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV Infection",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Nitazoxanide",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nitazoxanide",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2020-12-02",
      "completion_date": "2021-02-04",
      "has_results": true,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04605588"
    },
    {
      "nct_id": "NCT05893862",
      "title": "A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Elpipodect",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 107,
      "start_date": "2023-06-26",
      "completion_date": "2024-02-22",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-10-08T14:09:50.699Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Orange, California • Hallandale, Florida + 1 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05893862"
    }
  ]
}